The Power List is our chance to put the pharmaceutical and drug development industry’s inspirational thought leaders, opinion shapers and unsung heroes in the spotlight. We’re relying on you to ensure that the breadth of perspectives is as wide as possible!
personalized, responsive service and to improve the site, we remember and store information about how you use
The Medicine Maker
Welcome to the January issue. Upfront explores a collaborative project that aims to cut the cost of gene therapy and the EMA’s revised guidelines to better protect the environment. Minzhang Chen explains why the Chinese pharmaceutical market is already more advanced than many in the West imagine in “In My View,” while our cover feature explores the highs and lows for pharma in 2018. Ioannis Manolopoulos argues that serialization will certainly help in the battle against counterfeiters, but there are other steps that manufacturers can take, in NextGen; while George Chressanthis and Charlie Thompson explain why pharma could be the number one target for politicians in the US. In our latest Sitting Down With… Sir Alasdair Breckenridge considers how Brexit will impact pharma.